Ascendis Pharma A/S
NASDAQAscendis Pharma closed Friday at $260.75, up 13% on the week, marking its strongest seven-day stretch in months — yet the rally is colliding with a notable shift in the short book and a Street that remains divided on whether current prices already price in the pipeline upside. The sharpest signal this week is in options, and it points firmly toward risk-on. The put/call ratio has…
ASND short interest surges 20.8% in one week to 1.99M shares, driven by biotech sector volatility and competitive pressures in endocrinology therapeutics.
Snapshot as of 6 Aug 2026
Ascendis Pharma closed Friday at $260.75, up 13% on the week, marking its strongest seven-day stretch in months — yet the rally is colliding with a notable shift in the short book and a Street that remains divided on…
Ascendis Pharma reports Q1 2026 results today against a backdrop of strengthening short-side sentiment — but options traders are firmly in the bull camp. The standout signal heading into the print is the options…
Ascendis Pharma enters its Q1 2026 earnings call — scheduled for tomorrow, May 7 — with its ORTEX short score having nearly doubled over the past two weeks, setting up one of the more charged pre-earnings positioning…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for ASND — free to start on ORTEX.
Sign up for free →Open ASND on ORTEX